AMG 317

Drug Profile

AMG 317

Alternative Names: AMG-317; Anti-IL-4R - Amgen; Anti-interleukin-4 receptor antibody - Amgen

Latest Information Update: 30 Mar 2010

Price : $50

At a glance

  • Originator Amgen
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 26 Mar 2008 AMG-317 is still in phase II trials for asthma in the US
  • 18 Mar 2008 Pharmacokinetics, adverse events and pharmacodynamics data from two Phase-I trials and adverse events data from a Preclinical Trial in Asthma presented at the 64th Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI-2008) ,,
  • 31 Dec 2004 Phase-I clinical trials in Asthma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top